Medical University of Graz, Department for Internal Medicine
Welcome,         Profile    Billing    Logout  
 4 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Pieber, Thomas R
Meld-ATG, NCT04509791 / 2019-003265-17: MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D)

Active, not recruiting
2
114
Europe
Anti-Human Thymocyte Immunoglobulin, Rabbit, ATG
Universitaire Ziekenhuizen KU Leuven
Diabetes Mellitus, Type 1
12/24
12/24
Ver-A-T1D, NCT04545151 / 2020-000435-45: Verapamil SR in Adults With Type 1 Diabetes

Recruiting
2
138
Europe
Verapamil SR 120 mg, VeraHEXAL KHK 120 mg, Isoptin retard 120 mg, Placebo, Matching Placebo for Verapamil SR 120 mg
Medical University of Graz, Juvenile Diabetes Research Foundation
Diabetes Mellitus, Type 1
04/25
04/26
INNODIA, NCT03936634: An Innovative Approach Towards Understanding and Arresting Type 1 Diabetes

Recruiting
N/A
6000
Europe
University of Cambridge, Innovative Medicines Initiative, Juvenile Diabetes Research Foundation, The Leona M. and Harry B. Helmsley Charitable Trust
Type 1 Diabetes Mellitus
10/22
10/22
Sourij, Harald
NCT02817360: NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients

Recruiting
4
2400
Europe, RoW
RAS-antagonist and beta-blocker up-to maximal dosages, Enalapril 40mg/d, Ramipril 10mg/d, Lisinopril 40mg/d, Cilazapril 5mg/d, Perindopril 8mg/d, Captopril 150mg/d, Spirapril 24mg/d, Quinapril 40mg/d, Trandolapril 4mg/d, Zofenopril 60mg/d, Fosinopril 40mg/d, Candesartan 32mg/d, Valsartan 320mg/d, Irbesartan 300mg/d, Losartan 150mg/d, Eprosartan 800mg/d, Bisoprolol 10mg/d, Metoprololsuccinat 200mg/d, Carvedilol 50mg/d (100mg/d if weight is > 85kg), Nebivolol 10mg/d, RAS-antagonist and beta-blocker none or at stable dose
Martin Huelsmann
Heart Diseases, Diabetes Mellitus, Type 2
12/25
12/26
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Overweight and Obesity
02/29
02/29
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Recruiting
3
2620
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
04/25
12/25
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
GIRO, NCT05324488: Diabetes Registry Graz for Biomarker Research

Recruiting
N/A
2000
Europe
No intervention
Medical University of Graz
Type1diabetes, Type 2 Diabetes, Adiposity
01/35
02/35

Download Options